Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SMART Anti-IL-12: PDLI began a placebo-controlled U.K. Phase I testing in up to 36 healthy volunteers. The dose-escalation study will measure the safety and pha

Protein Design Labs Inc. (PDLI), Fremont,

Read the full 67 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE